EFG International AG Takes $1.15 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

EFG International AG purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the second quarter, Holdings Channel.com reports. The institutional investor purchased 1,840 shares of the biopharmaceutical company’s stock, valued at approximately $1,147,000.

Other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $5,682,636,000. Dodge & Cox boosted its holdings in shares of Regeneron Pharmaceuticals by 1.0% in the fourth quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock worth $3,547,791,000 after buying an additional 45,513 shares during the period. Franklin Resources Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 4.4% in the fourth quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock worth $1,975,990,000 after buying an additional 106,861 shares during the period. Nuveen LLC increased its position in shares of Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after acquiring an additional 835,240 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Regeneron Pharmaceuticals by 142.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock worth $1,504,991,000 after acquiring an additional 1,144,887 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Citigroup upped their price target on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Royal Bank Of Canada boosted their target price on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Morgan Stanley increased their target price on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Fifteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $800.36.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $814.79 on Thursday. The company has a 50 day simple moving average of $709.88 and a 200-day simple moving average of $717.69. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The firm has a market capitalization of $83.89 billion, a price-to-earnings ratio of 20.14, a price-to-earnings-growth ratio of 1.42 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $847.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. During the same period last year, the company posted $12.81 earnings per share. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.29%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,400 shares of company stock valued at $1,090,030 in the last quarter. Company insiders own 6.97% of the company’s stock.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Despite the setback, Wall Street remains generally constructive on Regeneron’s long-term growth prospects, and the shares have outperformed the broader S&P 500 over the past year. The company’s latest reported quarter also showed strong execution, with revenue up 16.7% year over year and EPS substantially above consensus estimates. Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?
• Neutral Sentiment: A reported August short-interest update showed zero shares sold short, but the figures appear incomplete or erroneous because the reported change was listed as “NaN.” It therefore provides little reliable information about current trading sentiment.
• Negative Sentiment: Several law firms announced or promoted a securities class action alleging that Regeneron misled investors about the viability and prospects of the Phase 3 Fianlimab-Libtayo melanoma study, including by emphasizing earlier-stage results and practice-changing expectations. The allegations have not been proven, but the litigation adds reputational, financial, and uncertainty-related overhang. Investors who purchased shares between August 1, 2025, and May 15, 2026, are being reminded of a September 14, 2026, deadline to seek lead-plaintiff status. Regeneron Investors: September 14, 2026 Lead Plaintiff Deadline

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.